We Are Crinetics


Crinetics is a pharmaceutical company that researches, discovers, and develops breakthrough therapies for patients with
rare endocrine diseases or tumors. We foster long-term relationships with healthcare practitioners to learn intimately
about the challenges patients face every day, then focus on developing game-changing therapies that improve their lives
in significant ways.

NANETS 2022 POSTER PRESENTATION


A Phase 2, Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome.

Presented by:

Aman Chauhan, M.D., study co-author
Director of NET Theranostics UK Markey Cancer CenterUniversity of Kentucky Healthcare
Friday, October 28, 5:15-7:00PM in The Poster Hall

AbstractPoster
200113amanchauhan134 4 1 uai

CONTACT US


Please fill out the information below and our medical affairs team will reach out to you about Crinetics and our Phase 2 and future Phase 3 studies with paltusotine for the treatment of carcinoid syndrome.

Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH-dependent Cushing's syndrome
PTH Antagonist, Hyperparathyroidism
SST3 Agonist, Polycystic Kidney Disease
TSH Antagonist, Graves' Disease, TED
Oral GLP-1 nonpeptide, Diabetes, Obesity
Oral GIP nonpeptide, Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH dependent Cushing's syndrome
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company